Collapse of Intra-Tumor Cooperation Induced by Engineered Defector Cells

Area of Science:

• Evolutionary biology
• Cancer research
• Game theory

Background:

• Anti-cancer therapies can inadvertently select for resistant cancer cells.
• Developing treatments resistant to evolutionary resistance is crucial for effective cancer therapy.
• Intra-tumor cooperation among cancer cells can promote tumor growth and treatment evasion.

Purpose of the Study:

• To investigate the in vitro efficacy of impairing intra-tumor cooperation using genetically modified non-producer cancer cells.
• To assess the impact of engineered cells on tumor growth and proliferation across different cancer types.
• To explore the role of growth factor production cost/benefit ratios and public goods game dynamics in tumor cooperation collapse.

Main Methods:

• In vitro experiments using four cancer types: neuroendocrine pancreatic cancer, mesothelioma, lung adenocarcinoma, and multiple myeloma.
• Introduction of a small fraction of genetically modified non-producer cells into cancer cell populations.
• Analysis of cell proliferation, producer clone reduction, and cooperation dynamics based on evolutionary game theory principles.

Main Results:

• A reduction or complete eradication of producer clones and decreased cell proliferation was observed in some, but not all, tested cancer types.
• The collapse of intra-tumor cooperation was found to be dependent on the cost/benefit ratio of growth factor production.
• Stable cooperation could be disrupted by increasing the availability of growth factors, perturbing the public goods game equilibrium.

Conclusions:

• Engineering cancer cells to disrupt intra-tumor cooperation is a potential anti-cancer strategy, but its success is context-dependent.
• The cost/benefit ratio of essential growth factor production is a critical factor in determining the collapse of tumor cooperation.
• Further research is needed to identify high-cost, essential growth factors for targeted therapeutic engineering.